CD24 senescent neutrophils as key players in myelofibrosis
In this issue of Blood, Khatib-Massalha et al show that upregulation of CD24 on JAK2V617F neutrophils inhibits their clearance, leading to an accumulation
Related Articles
Counterpoint: the design and interpretation of blood transfusion randomized clinical trials
Designing randomized clinical trials (RCTs) that are fit for purpose to answer burning questions in routine practice is difficult, and the interpretation o
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
Key PointsS-MRD negativity <10–5 is the best predictor of outcomes in newly diagnosed multiple myeloma.Similar results are seen among patients who achie
Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24
Key PointsJAK2V617F neutrophils evade homeostatic clearance and accumulate in MPN owing to JAK2-STAT5–dependent upregulation of CD24.CD24 antibody blockade
Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI
Key PointsComplement MAC triggers the development of anti-CD36–mediated murine TRALI.Blockage of MAC formation by monoclonal anti-C7 prevented and ameliora
Cracking TRALI: targeting the membrane attack complex
In this issue of Blood, Chen et al have identified the membrane attack complex (MAC) as a key mediator in anti-CD36-mediated murine transfusion-related acu
Keep your distance or lose control
In this issue of Blood, Felder et al1 demonstrate that, for normal developmental control of globin gene expression, the enhancer (locus control region [LCR
ASH Clinical News Seeks Associate Editors for 2026-2028 Terms | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) is in search of Associate Editors to join ASH Clinical News, the Society’s monthly news magazine for the broader…
Sustained MRD negativity: robust, not all-powerful
In this issue of Blood, Giri et al report that sustained minimal residual disease (MRD) negativity at the 10−5 threshold is the most effective predictor…
Myeloma: a sky full of MRD stars
In this issue of Blood, Corre et al1 present the final, long-term minimal residual disease (MRD) and progression-free survival (PFS) results from the multi
Second Look- Rapid Review Program | Journals Gateway | American Society of Hematology
Second Look- Rapid Review Program | Journals Gateway | American Society of Hematology Second Look – Rapid Response Program The Second Look program provides you…